Methadone is an evidence-based treatment for opioid use disorder (OUD) and pain management. Methadone for OUD may be difficult for some patients to access, particularly those in rural areas.
Objective:
The purpose of this study was to characterize methadone distribution patterns between 2017 and 2019 across the United States.
Methods:
The US Drug Enforcement Administration’s Automated Reports and Consolidated Ordering System was used to acquire the number of opioid treatment programs (OTPs) per state and methadone distribution weight in grams. Methadone distributions by weight, corrected for state population and number of OTPs, were compared from 2017 to 2019 between states, within regions, and nationally.
Results:
The national distribution of methadone increased +12.3% for OTPs but decreased −34.6% for pain. Whereas all states saw a decrease in pain distribution, the Northeast showed a significantly smaller decrease than all other regions. Additionally, the majority of states experienced an increase in distribution for OTPs, and most states demonstrated a relatively stable or increasing number of OTPs, with an +11.5% increase nationally. The number of OTPs per 100K state population ranged from 2.1 in Rhode Island to 0.0 in Wyoming.
Conclusion and Relevance:
Although methadone distribution for OUD was increasing in the United States, the pronounced regional disparities identified warrant further consideration to improve patient access to this evidence-based pharmacotherapy, particularly in the Midwest and West regions. Greater implementation of telehealth and involvement of primary care into opioid treatment practice offer possible solutions to eliminating geographical treatment barriers.
AndersonIBKearneyTE.Use of methadone. West J Med. 2000;172:43-46. doi:10.1136/ewjm.172.1.43
2.
MarschLA.The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93:515-532. doi:10.1046/j.1360-0443.1998.9345157.x
3.
MercadanteSBrueraE.Methadone as a first-line opioid in cancer pain management: a systematic review. J Pain Symptom Manage. 2018;55:998-1003. doi:10.1016/j.jpainsymman.2017.10.017
OtiashviliDPiralishviliGSikharulidzeZKamkamidzeGPooleSWoodyGE.Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior—outcomes of a randomized trial. Drug Alcohol Depend. 2013;133:376-382. doi:10.1016/j.drugalcdep.2013.06.024
6.
SalsitzEWiegandT. Pharmacotherapy of opioid addiction: “putting a real face on a false demon.”J Med Toxicol. 2016;12:58-63. doi:10.1007/s13181-015-0517-5
7.
SmithCBR. Socio-spatial stigmatization and the contested space of addiction treatment: remapping strategies of opposition to the disorder of drugs. Soc Sci Med. 2010;70:859-866. doi:10.1016/j.socscimed.2009.10.033
8.
HydeTBekoe-TabiriAKropp LopezA, et al. County and demographic differences in drug arrests and controlled substance use in Maine. medRXiv. Published online August 22, 2020. doi:10.1101/2020.08.19.20178079
9.
Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2019, Data on Substance Abuse Treatment Facilities. Substance Abuse and Mental Health Services Administration; 2020.
10.
PiperBJShahDTSimoyanOMMcCallKLNicholsSD.Trends in medical use of opioids in the US, 2006-2016. Am J Prev Med. 2018;54:652-660. doi:10.1016/j.amepre.2018.01.034
11.
PiperBJMcCallKLKoganLHellerP.Assessment of controlled substance distribution to US veterinary teaching institutions from 2006 to 2019. Front Vet Sci. 2020;7:615646. doi:10.3389/fvets.2020.615646
12.
CabreraFFGamarraERGarciaTE, et al. Opioid distribution trends (2006-2017) in the US territories. PeerJ. 2019;7:e6272. doi:10.7717/peerj.6272
13.
JonesCMBaldwinGTManocchioTWhiteJOMackKA.Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths—United States, 2002-2014. MMWR Morb Mortal Wkly Rep. 2016;65:667-671. doi:10.15585/mmwr.mm6526a2
BoyerEW.Management of opioid analgesic overdose. N Engl J Med. 2012;367:146-155. doi:10.1056/NEJMra1202561
16.
AboukRPaculaRLPowellD.Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. JAMA Intern Med. 2019;179:805-811. doi:10.1001/jamainternmed.2019.0272
17.
AlderksCE.Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003-2015 (update). In: The CBHSQ Report. Substance Abuse and Mental Health Services Administration; 2017.
18.
HaffajeeRLLinLABohnertASBGoldstickJE.Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Netw Open. 2019;2:e196373. doi:10.1001/jamanetworkopen.2019.6373
19.
Pashmineh AzarARCruz-MullaneAPoddJC, et al. Rise and regional disparities in buprenorphine utilization in the United States. Pharmacoepidemiol Drug Saf. 2020;29:708-715. doi:10.1002/pds.4984
20.
KleinmanRA.Comparison of driving times to opioid treatment programs and pharmacies in the US. JAMA Psychiatry. 2020;77:1163-1171. doi:10.1001/jamapsychiatry.2020.1624
21.
JoudreyPJChadiNRoyP, et al. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: a cross-sectional study. Drug Alcohol Depend. 2020;211:107968. doi:10.1016/j.drugalcdep.2020.107968
22.
FonsecaJChangAChangF.Perceived barriers and facilitators to providing methadone maintenance treatment among rural community pharmacists in Southwestern Ontario. J Rural Health. 2018;34:23-30. doi:10.1111/jrh.12264
KiangMVBasuSChenJAlexanderMJ.Assessment of changes in the geographical distribution of opioid-related mortality across the United States by opioid type, 1999-2016. JAMA Netw Open. 2019;2:e190040. doi:10.1001/jamanetworkopen.2019.0040
25.
AtluriSSudarshanGManchikantiL.Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician. 2014;17:E119-E128.
26.
BokhariFMayesRSchefflerRM.An analysis of the significant variation in psychostimulant use across the US. Pharmacoepidemiol Drug Saf. 2005;14:267-275. doi:10.1002/pds.980
27.
ToceMSChaiPRBurnsMMBoyerEW.Pharmacologic treatment of opioid use disorder: a review of pharmacotherapy, adjuncts, and toxicity. J Med Toxicol. 2018;14:306-322. doi:10.1007/s13181-018-0685-1
DowellDHaegerichTMChouR.CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep. 2016;65:1-49. doi:10.15585/mmwr.rr6501e1
30.
SoelbergCDBrownREJrDu VivierDMeyerJERamachandranBK.The US opioid crisis: current federal and state legal issues. Anesth Analg. 2017;125:1675-1681. doi:10.1213/ANE.0000000000002403
RawsonRCousinsSJMcCannMPearceRVan DonselA.Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system. J Subst Abuse Treat. 2019;97:84-90. doi:10.1016/j.jsat.2018.11.003
36.
MieleGMCatonLFreeseTE, et al. Implementation of the hub and spoke model for opioid use disorders in California: rationale, design and anticipated impact. J Subst Abuse Treat. 2020;108:20-25. doi:10.1016/j.jsat.2019.07.013
37.
ReifSBrolinMFStewartMTFuchsTJSpeakerEMazelSB.The Washington state hub and spoke model to increase access to medication treatment for opioid use disorders. J Subst Abuse Treat. 2020;108:33-39. doi:10.1016/j.jsat.2019.07.007
AndrillaCHAMooreTEPattersonDGLarsonEH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2019;35:108-112. doi:10.1111/jrh.12307
40.
HserYIEvansEHuangD, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016;111:695-705. doi:10.1111/add.13238
41.
MattickRPKimberJBreenCDavoliM.Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004;(3): CD002207. doi:10.1002/14651858.CD002207.pub2
42.
Brinkley-RubinsteinLMcKenzieMMacmaduA, et al. A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: findings at 12 months post-release. Drug Alcohol Depend. 2018;184:57-63. Published correction appears in Drug Alcohol Depend. 2018;186:9.
43.
SordoLBarrioGBravoMJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:1550.
44.
SametJHBotticelliMBharelM.Methadone in primary care—one small step for Congress, one giant leap for addiction treatment. N Engl J Med. 2018;379:7-8.
45.
CatonLChengHGarneauC, et al. COVID-19 adaptations in the care of patients with opioid use disorder: a survey of California primary care clinics. J Gen Intern Med. 2021;36: 998-1005.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
